latest update:
[TrialBase DB]

trial summary · NCT07741253

PRECISE-AFMR I: Transcatheter Mitral Valve Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation in Patients at High Surgical Risk

PRECISE-AFMR I: A Prospective Randomized Controlled Trial of Transcatheter Mitral Valve Edge-to-Edge Repair in Patients With Atrial Functional Mitral Regurgitation at High Surgical Risk

Trial record from the TrialBase DB dataset, status RECRUITING, condition Atrial Functional, sponsored by China National Center for Cardiovascular Diseases. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07741253phase —enrollment 182start 2026-10-25

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Atrial functional mitral regurgitation (AFMR) develops when enlargement and remodeling of the left atrium and mitral annulus prevent the mitral valve leaflets from closing completely, allowing blood to leak backward through the valve. For patients with significant AFMR who remain symptomatic despite medical treatment and are at high risk for surgery, it is uncertain whether adding transcatheter mitral valve edge-to-edge repair (TEER), a catheter-based procedure that brings the mitral valve leaflets together, provides better outcomes than medical treatment alone. PRECISE-AFMR I is a prospective, multicenter, randomized study that will enroll 182 adults with moderate-to-severe or severe AFMR, high or prohibitive surgical risk, and mitral valve anatomy suitable for TEER. Participants will be assigned in a 1:1 ratio to receive TEER plus optimized guideline-directed medical therapy (GDMT) or optimized GDMT alone. All participants will receive standardized medical care and will be followed for 12 months. The main effectiveness outcome is the occurrence of death from any cause or hospitalization for heart failure within 12 months. The main safety outcome is the occurrence of major device-related adverse events within 12 months. The study will also assess mitral regurgitation severity, symptoms, functional capacity, quality of life, heart failure events, and use of health care resources.

Source record: https://clinicaltrials.gov/study/NCT07741253

Facts

registry idNCT07741253
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionAtrial Functional
sponsorChina National Center for Cardiovascular Diseases
sponsor classOTHER_GOV
enrollment182
start date2026-10-25
primary completion2027-12
completion2027-12
results postednot reported

Conditions

  • Atrial Functional
  • Mitral Regurgitation (MR)

Interventions

  • Transcatheter Edge-to-Edge Repair

Countries

  • China

Intervention types: DEVICE

Work with this record